The selective expression of PSMA in the tumor-associated vasculature in cases of HCC, and not in the tumor cells themselves, indicates PSMA may be an effective antiangiogenic treatment target for HCC [20–22]. This evidence concerns the gene FOLH1 and hepatocellular carcinoma.